{"protocolSection":{"identificationModule":{"nctId":"NCT02347917","orgStudyIdInfo":{"id":"D8807005"},"organization":{"fullName":"Sumitomo Pharma Co., Ltd.","class":"INDUSTRY"},"briefTitle":"A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma","officialTitle":"A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma"},"statusModule":{"statusVerifiedDate":"2022-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-05-31","type":"ACTUAL"},"completionDateStruct":{"date":"2018-05-31","type":"ACTUAL"},"studyFirstSubmitDate":"2015-01-21","studyFirstSubmitQcDate":"2015-01-26","studyFirstPostDateStruct":{"date":"2015-01-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-05-10","resultsFirstSubmitQcDate":"2021-09-05","resultsFirstPostDateStruct":{"date":"2021-10-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-04-09","lastUpdatePostDateStruct":{"date":"2022-04-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sumitomo Pharma Co., Ltd.","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM)."},"conditionsModule":{"conditions":["Malignant Pleural Mesothelioma","Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":28,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BBI608 puls pemetrexed and cisplatin","type":"EXPERIMENTAL","interventionNames":["Drug: BBI608","Drug: Pemetrexed","Drug: Cisplatin"]}],"interventions":[{"type":"DRUG","name":"BBI608","description":"480 mg orally twice daily (960 mg total daily dose)","armGroupLabels":["BBI608 puls pemetrexed and cisplatin"]},{"type":"DRUG","name":"Pemetrexed","description":"500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).","armGroupLabels":["BBI608 puls pemetrexed and cisplatin"]},{"type":"DRUG","name":"Cisplatin","description":"75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).","armGroupLabels":["BBI608 puls pemetrexed and cisplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs)","description":"An AE is any untoward medical occurrence in a study subject administered an investigational drug and which does not necessarily have a causal relationship with this treatment.\n\nA SAE was an AE that met one or more of the following criteria:\n\n* Results in death\n* Is life-threatening\n* Requires hospitalization or prolongation of existing hospitalization\n* Results in persistent or significant disability or incapacity\n* Is a congenital anomaly or birth defect\n* Is an important medical event that may jeopardize the subject or may require a medical or surgical intervention to prevent one of the outcomes listed above. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization.\n\nAn ADR was defined as adverse events assessed to be related to the investigational drug","timeFrame":"Between initial dosing of the investigational drug and final evaluation in the follow-up observation period, about 17 months"},{"measure":"Phase 1 Part: Number of Participants With Dose-limiting Toxicities (DLTs)","description":"DLT was defined as an adverse event meeting any of the following that occurred during the DLT evaluation period in any participants given BBI608 with the causal relationship to BBI608 assessed as \"Definite,\" \"Probable,\" or \"Possible.\" The severity of adverse events was graded according to the CTCAE v4.0-JCOG.\n\n* Grade 4 neutropenia persisting for ≥ 7 days\n* Grade ≥ 3 febrile neutropenia persisting for ≥ 5 days\n* Grade 3 thrombocytopenia requiring platelet transfusions, grade 4 thrombocytopenia\n* Grade ≥ 3 non-hematotoxicity except the following:\n\n  1. Inappetence, nausea, vomiting and electrolyte abnormality which, within 3 days of onset, improved to grade ≤ 2 or resolved after appropriate treatment\n  2. Diarrhoea and fatigue which, within 5 days of onset, improved to grade ≤ 2 or resolved after appropriate treatment\n* Other clinically significant signs in the opinion of the investigator","timeFrame":"From Day 1 of Cycle 1 to Day 24 pre-dose examination (23 days)"},{"measure":"Phase 1 Part: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of BBI608 When Administered With Pem and CDDP","timeFrame":"Cycle 1 Day 1 (Cmax only) and Day 23"},{"measure":"Phase 1 Part: Area Under the Concentration-time Curve","description":"AUC0-12: Area under the concentration-time curve from time zero to 12 hours, AUC0-24: Area under the concentration-time curve from time zero to 24 hours, AUC0-inf: Area under the concentration-time curve from time zero to infinity","timeFrame":"Cycle 1 Day 1 and Day 23"},{"measure":"Phase 2 Part: Progression-free Survival (PFS)","description":"PFS was defined as the time from BBI608 administration to documented PD (as assessed according to the mRECIST or RECIST 1.1) or death, whichever is earlier. The result of imaging assessment by the imaging assessment committee was used for phase 2 part.","timeFrame":"From BBI608 administration to documented PD or death, whichever is earlier, about 17 months"}],"secondaryOutcomes":[{"measure":"Best Overall Response","description":"The best overall response is the best response recorded from the start of the study treatment until the end of treatment. The RECIST 1.1 was used for the evaluation of tumor response and overall response in patients with NSCLC, and also the evaluation of any non-pleural lesions in patients with MPM. The mRECIST was used for the evaluation of tumor response and overall response in patients with MPM. The result of imaging assessment by study site was used for phase 1 part, and the result of imaging assessment by the imaging assessment committee was used for phase 2 part.","timeFrame":"Every 6 weeks from the first dose of BBI608 until Week 30, and every 9 weeks from Week 31."},{"measure":"Response Rate (RR) and Disease Control Rate (DCR)","description":"Response rate (RR): Proportion of subjects whose best overall response is CR or PR.\n\nDisease control rate (DCR): Proportion of subjects whose best overall response is CR, PR or SD.\n\nThe result of imaging assessment by study site was used for phase 1 part, and the result of imaging assessment by the imaging assessment committee was used for phase 2 part.","timeFrame":"From BBI608 administration to death from any cause, about 17 months"},{"measure":"Overall Survival(OS)","description":"OS was defined as the time from BBI608 administration to death from any cause. Participants alive at final observation or lost to follow-up were censored at their last contact (i.e., visit or telephone) date.","timeFrame":"From BBI608 administration to death from any cause, up to 31 months"},{"measure":"Respiratory Function Tests (Vital Capacity [VC] and Forced Vital Capacity [FVC])","timeFrame":"Every 6 weeks from the first dose of BBI608 until Week 30, and then every 9 weeks from Week 31 [Actually up to Week 111]"},{"measure":"Respiratory Function Tests (Forced Expiratory Volume in the First Second [FEV1])","timeFrame":"Every 6 weeks from the first dose of BBI608 until Week 30, and then every 9 weeks from Week 31 [Actually up to Week 111]"}]},"eligibilityModule":{"eligibilityCriteria":"Phase 1\n\nInclusion Criteria:\n\n* Histologically confirmed diagnosis of Malignant Pleural Mesothelioma (MPM) or Non-Small Cell Lung Cancer (NSCLC).\n* Measurable disease as defined by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) for MPM or the RECIST 1.1 for NSCLC.\n* ≥ 20 years of age.\n* Provision of written informed consent.\n* For male or female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 30 days after the last protocol treatment dose.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Hemoglobin (Hb) ≥ 9.0 g/dL.\n* Neutrophils ≥ 1500/μL.\n* Platelets ≥ 100,000/μL.\n* Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5-fold the upper limit of normal range (ULN) \\[≤ 5-fold ULN with any liver metastasis\\].\n* Total bilirubin ≤ 1.5-fold ULN.\n* Creatinine clearance (estimated value) ≥ 60 mL/min.\n* Life expectancy ≥ 3 months.\n* Females of childbearing potential have a negative urine pregnancy test.\n\nPhase 2\n\nInclusion Criteria:\n\n* Histologically confirmed diagnosis of MPM.\n* Treatment naïve and not indicated for resection.\n* Measurable disease as defined by the modified RECIST.\n* ≥ 20 years of age.\n* Provision of written informed consent.\n* For male or female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 30 days after the last protocol treatment dose.\n* ECOG Performance Status of 0 or 1.\n* Hb ≥ 9.0 g/dL.\n* Neutrophils ≥ 1500/μL.\n* Platelets ≥ 100,000/μL.\n* AST and ALT ≤ 2.5-fold ULN \\[≤ 5-fold ULN for patients with any liver metastasis\\].\n* Total bilirubin ≤ 1.5-fold ULN.\n* Creatinine clearance (estimated value) \\> 60 mL/min.\n* Life expectancy ≥ 3 months.\n* Females of childbearing potential have a negative urine pregnancy test.\n\nBoth Phase 1 and 2\n\nExclusion Criteria:\n\n* Prior anti-cancer chemotherapy and radiotherapy.\n* Prior hormonal therapy, immunotherapy, thermotherapy, operation.\n* Any brain metastasis requiring treatment or symptomatic.\n* Active multiple primary cancers.\n* Crohn's disease, ulcerative colitis, small intestine resection.\n* Abnormal ECGs.\n* Prior myocardial infarction.\n* Current use of antiarrhythmic medication.\n* Uncontrolled concurrent diseases.\n* Known severe hypersensitivity to pemetrexed, cisplatin or other drugs containing platinum.\n* Women who are pregnant or breastfeeding.\n* Received other investigational drugs.\n* Unable or unwilling to swallow BBI608 capsules daily.\n* Prior treatment with BBI608.\n* Ineligible for participation in the study in the opinion of the Investigators.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Sumitomo Pharma Co., Ltd. Japan","affiliation":"Sumitomo Pharma Co., Ltd.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"National Cancer Center Hospital East","city":"Chiba","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"National Cancer Center Hospital","city":"Tokyo","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"This clinical study consisted of two parts: Phase 1 and Phase 2. The study proceeded to Phase 2 part after Phase 1 part demonstrated the tolerability of BBI608 combined with Pem plus CDDP based on complete assessment of DLT. Participants were NOT enrolled in Phase 1 and Phase 2 in duplicate.","recruitmentDetails":"The study conducted from February 2015 to December 2017 and a total of 28 participants were enrolled at 9 medical institutions in Japan.","groups":[{"id":"FG000","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"FG001","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"24"}]},{"type":"Discontinued beforeBBI608 Administration","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Start BBI608 Administration","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"24"}]},{"type":"Discontinued in DLT Evaluation Period","comment":"DLT was assessed in Phase 1 part only.","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Complete DLT Evaluation Period","comment":"DLT was assessed in Phase 1 part only.","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Discontinued After BBI608 Administration","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"24"}]},{"type":"Discontinued Before Survival Observation","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"COMPLETED","comment":"Complete survival observation","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"23"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Participants were NOT enrolled in Phase 1 and Phase 2 in duplicate.","groups":[{"id":"BG000","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"BG001","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"64.5","spread":"5.00"},{"groupId":"BG001","value":"65.6","spread":"10.71"},{"groupId":"BG002","value":"65.5","spread":"9.854"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"25"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Primary cancer","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"categories":[{"title":"MPM","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"25"}]},{"title":"NSCLC","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"58.53","spread":"10.278"},{"groupId":"BG001","value":"63.11","spread":"7.661"},{"groupId":"BG002","value":"62.45","spread":"8.025"}]}]}]},{"title":"ECOG PS","description":"The Eastern Cooperative Oncology Group (ECOG) performance status measures patients' disease status on the following scale: 0=Fully active, able to carry on all pre-disease performance without restriction; 1=Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2=Ambulatory and capable of all selfcare, unable to carry out any work activities. Up and about \\>50% of waking hours; 3=Capable of only limited selfcare, confined to bed or chair \\>50% of waking hours; 4=Completely disabled. Totally confined to bed or chair; 5=Dead","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"categories":[{"title":"0","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"14"}]},{"title":"1","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"14"}]},{"title":"2<=","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Disease classification","description":"Most types of cancer have four stages: stages I (1) to IV (4). Some cancers also have a stage 0 (zero). Lower stages indicate that the disease is more localized, or contained, whereas higher stages refer to cancers that have spread into other areas of the body: Stage 0 = cancer in situ, which means \"in place\"; Stage I = a small cancer or tumor that has not grown deeply into nearby tissues; Stage II and III = larger cancers or tumors that have grown more deeply into nearby tissue; Stage IV = the cancer has spread to other organs or parts of the body.","populationDescription":"Of 4 participants in Phase 1 part, 3 participants with NSCLC and 1 participant with MPM enrolled.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"MPM","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"25"}]}],"categories":[{"title":"STAGE I","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"STAGE II","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]},{"title":"STAGE III","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"}]},{"title":"STAGE IV","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"18"}]}]},{"title":"NSCLC","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}],"categories":[{"title":"STAGE I","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"STAGE II","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"STAGE III","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"STAGE IV","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Tissue classification (MPM)","populationDescription":"Of 4 participants in Phase 1 part, 3 participants with NSCLC and 1 participant with MPM enrolled.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"25"}]}],"categories":[{"title":"EPITHELIOID","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"17"}]},{"title":"SARCOMATOID","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]},{"title":"BIPHASIC","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"}]},{"title":"OTHER","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Tissue classification (NSCLC)","populationDescription":"Of 4 participants in Phase 1 part, 3 participants with NSCLC and 1 participant with MPM enrolled.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}],"categories":[{"title":"ADENOCARCINOMA","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]},{"title":"SQUAMOUS CELL CARCINOMA","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"LARGE CELL CARCINOMA","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"OTHER","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Metastases","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"14"}]},{"title":"No","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"14"}]}]}]},{"title":"Disease duration","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"month","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"3.91","spread":"2.866"},{"groupId":"BG001","value":"0.91","spread":"0.726"},{"groupId":"BG002","value":"1.34","spread":"1.562"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs)","description":"An AE is any untoward medical occurrence in a study subject administered an investigational drug and which does not necessarily have a causal relationship with this treatment.\n\nA SAE was an AE that met one or more of the following criteria:\n\n* Results in death\n* Is life-threatening\n* Requires hospitalization or prolongation of existing hospitalization\n* Results in persistent or significant disability or incapacity\n* Is a congenital anomaly or birth defect\n* Is an important medical event that may jeopardize the subject or may require a medical or surgical intervention to prevent one of the outcomes listed above. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization.\n\nAn ADR was defined as adverse events assessed to be related to the investigational drug","populationDescription":"Safety analysis populations (Phase 1 part)","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Between initial dosing of the investigational drug and final evaluation in the follow-up observation period, about 17 months","groups":[{"id":"OG000","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"title":"Any AEs","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"AEs leading to death","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Serious AEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"AEs leading to drug withdrawn (BBI608)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"AEs leading to drug interrupted (BBI608)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"AEs leading to dose reduced (BBI608)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Any ADRs","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"ADRs leading to death","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Serious ADRs","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"ADRs leading to drug withdrawn (BBI608)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"ADRs leading to drug interrupted (BBI608)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"ADRs leading to dose reduced (BBI608)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Phase 1 Part: Number of Participants With Dose-limiting Toxicities (DLTs)","description":"DLT was defined as an adverse event meeting any of the following that occurred during the DLT evaluation period in any participants given BBI608 with the causal relationship to BBI608 assessed as \"Definite,\" \"Probable,\" or \"Possible.\" The severity of adverse events was graded according to the CTCAE v4.0-JCOG.\n\n* Grade 4 neutropenia persisting for ≥ 7 days\n* Grade ≥ 3 febrile neutropenia persisting for ≥ 5 days\n* Grade 3 thrombocytopenia requiring platelet transfusions, grade 4 thrombocytopenia\n* Grade ≥ 3 non-hematotoxicity except the following:\n\n  1. Inappetence, nausea, vomiting and electrolyte abnormality which, within 3 days of onset, improved to grade ≤ 2 or resolved after appropriate treatment\n  2. Diarrhoea and fatigue which, within 5 days of onset, improved to grade ≤ 2 or resolved after appropriate treatment\n* Other clinically significant signs in the opinion of the investigator","populationDescription":"DLT evaluable population (3 participants with NSCLC in Phase 1 part)\n\n1 participant with MPM was excluded from DLT evaluable population because the BBI608 treatment compliance rate during DLT evaluation period did not meet the rate of 80% which of assessable for DLT and no adverse events assessed as DLT occurred.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 of Cycle 1 to Day 24 pre-dose examination (23 days)","groups":[{"id":"OG000","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Phase 1 Part: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of BBI608 When Administered With Pem and CDDP","populationDescription":"Pharmacokinetic (PK) analysis population\n\n1 participant with MPM of 4 participants in the pharmacokinetic analysis population completed BBI608 administration on Day 14 in Cycle 1 and therefore was not included in the analysis for Cmax and AUC on Day 23.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"ng/mL","timeFrame":"Cycle 1 Day 1 (Cmax only) and Day 23","groups":[{"id":"OG000","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"title":"Day 1: Cmax","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"307.5","lowerLimit":"251","upperLimit":"380"}]}]},{"title":"Day 23: Cmax","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"473.7","lowerLimit":"316","upperLimit":"643"}]}]},{"title":"Day 23: Cmin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"196.1","lowerLimit":"30.4","upperLimit":"392.0"}]}]}]},{"type":"PRIMARY","title":"Phase 1 Part: Area Under the Concentration-time Curve","description":"AUC0-12: Area under the concentration-time curve from time zero to 12 hours, AUC0-24: Area under the concentration-time curve from time zero to 24 hours, AUC0-inf: Area under the concentration-time curve from time zero to infinity","populationDescription":"Pharmacokinetic (PK) analysis population\n\n1 participant with MPM of 4 participants in the pharmacokinetic analysis population completed BBI608 administration on Day 14 in Cycle 1 and therefore was not included in the analysis for Cmax and AUC on Day 23.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"h*ng/mL","timeFrame":"Cycle 1 Day 1 and Day 23","groups":[{"id":"OG000","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"title":"Day 1: AUC0-12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1814.3","lowerLimit":"900","upperLimit":"2443"}]}]},{"title":"Day 1: AUC0-24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2223.8","lowerLimit":"1005","upperLimit":"3060"}]}]},{"title":"Day 1: AUC0-inf","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2413.5","lowerLimit":"1141","upperLimit":"3536"}]}]},{"title":"Day 23: AUC0-12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3797.0","lowerLimit":"1788","upperLimit":"5725"}]}]},{"title":"Day 23: AUC0-24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6103.7","lowerLimit":"1936","upperLimit":"9948"}]}]},{"title":"Day 23: AUC0-inf","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10762.7","lowerLimit":"1962","upperLimit":"20834"}]}]}]},{"type":"PRIMARY","title":"Phase 2 Part: Progression-free Survival (PFS)","description":"PFS was defined as the time from BBI608 administration to documented PD (as assessed according to the mRECIST or RECIST 1.1) or death, whichever is earlier. The result of imaging assessment by the imaging assessment committee was used for phase 2 part.","populationDescription":"modified ITT population. Efficacy was analyzed using the efficacy analysis population (i.e., modified ITT population; mITT), separately for Phase 1 part (n=4), Phase 2 part (n=24) and Phase 2 part including 1 participant with MPM in Phase 1 part (n=25).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"month","timeFrame":"From BBI608 administration to documented PD or death, whichever is earlier, about 17 months","groups":[{"id":"OG000","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG001","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part Including 1 Participant With MPM in Phase 1 Part)","description":"Participants orally received BBI608(480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.59","lowerLimit":"2.89","upperLimit":"NA","comment":"Not reached"},{"groupId":"OG001","value":"5.59","lowerLimit":"2.89","upperLimit":"NA","comment":"Not reached"}]}]}]},{"type":"SECONDARY","title":"Best Overall Response","description":"The best overall response is the best response recorded from the start of the study treatment until the end of treatment. The RECIST 1.1 was used for the evaluation of tumor response and overall response in patients with NSCLC, and also the evaluation of any non-pleural lesions in patients with MPM. The mRECIST was used for the evaluation of tumor response and overall response in patients with MPM. The result of imaging assessment by study site was used for phase 1 part, and the result of imaging assessment by the imaging assessment committee was used for phase 2 part.","populationDescription":"modified ITT population. Efficacy was analyzed using the efficacy analysis population (i.e., modified ITT population; mITT), separately for Phase 1 part (n=4), Phase 2 part (n=24) and Phase 2 part including 1 participant with MPM in Phase 1 part (n=25).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Every 6 weeks from the first dose of BBI608 until Week 30, and every 9 weeks from Week 31.","groups":[{"id":"OG000","title":"NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG001","title":"MPM: BBI608 + Pem +CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG002","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG003","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG004","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part Including Participants With MPM in Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"}]}],"classes":[{"categories":[{"title":"Complete response (CR)","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]},{"title":"Partial response (PR)","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"}]},{"title":"Stable disease (SD)","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"11"}]},{"title":"Progressive disease (PD)","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]},{"title":"Not evaluated (NE)","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"}]}]}]},{"type":"SECONDARY","title":"Response Rate (RR) and Disease Control Rate (DCR)","description":"Response rate (RR): Proportion of subjects whose best overall response is CR or PR.\n\nDisease control rate (DCR): Proportion of subjects whose best overall response is CR, PR or SD.\n\nThe result of imaging assessment by study site was used for phase 1 part, and the result of imaging assessment by the imaging assessment committee was used for phase 2 part.","populationDescription":"modified ITT population. Efficacy was analyzed using the efficacy analysis population (i.e., modified ITT population; mITT), separately for Phase 1 part (n=4), Phase 2 part (n=24) and Phase 2 part including 1 participant with MPM in Phase 1 part (n=25).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From BBI608 administration to death from any cause, about 17 months","groups":[{"id":"OG000","title":"NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG001","title":"MPM: BBI608 + Pem +CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG002","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG003","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG004","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part Including 1 Participant With MPM in Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"}]}],"classes":[{"title":"Response rate (RR)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"}]}]},{"title":"Disease control rate (DCR)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"19"}]}]}]},{"type":"SECONDARY","title":"Overall Survival(OS)","description":"OS was defined as the time from BBI608 administration to death from any cause. Participants alive at final observation or lost to follow-up were censored at their last contact (i.e., visit or telephone) date.","populationDescription":"modified ITT population. Efficacy was analyzed using the efficacy analysis population (i.e., modified ITT population; mITT), separately for Phase 1 part (n=4), Phase 2 part (n=24) and Phase 2 part including 1 participant with MPM in Phase 1 part (n=25).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"month","timeFrame":"From BBI608 administration to death from any cause, up to 31 months","groups":[{"id":"OG000","title":"NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG001","title":"MPM: BBI608 + Pem +CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG002","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG003","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG004","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part Including 1 Participant With MPM in Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.81","lowerLimit":"19.4","upperLimit":"27.8"},{"groupId":"OG001","value":"30.1","lowerLimit":"30.1","upperLimit":"30.1"},{"groupId":"OG002","value":"NA","lowerLimit":"19.4","upperLimit":"30.1","comment":"Not calculated for total population in Phase 1 part because calculated for each cancer type (i.e., NSCLC and MPM separately)"},{"groupId":"OG003","value":"12.14","lowerLimit":"3.0","upperLimit":"28.6"},{"groupId":"OG004","value":"12.75","lowerLimit":"3.0","upperLimit":"30.1"}]}]}]},{"type":"SECONDARY","title":"Respiratory Function Tests (Vital Capacity [VC] and Forced Vital Capacity [FVC])","populationDescription":"modified ITT population. Efficacy was analyzed using the efficacy analysis population (i.e., modified ITT population; mITT), separately for Phase 1 part (n=4), Phase 2 part (n=24) and Phase 2 part including 1 participant with MPM in Phase 1 part (n=25). In respiratory function tests, data from 1 participant with MPM in Phase 1 part were not collected.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"mL","timeFrame":"Every 6 weeks from the first dose of BBI608 until Week 30, and then every 9 weeks from Week 31 [Actually up to Week 111]","groups":[{"id":"OG000","title":"NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG001","title":"MPM: BBI608 + Pem +CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG002","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG003","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG004","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part Including 1 Participant With MPM in Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"}]}],"classes":[{"title":"The change from baseline in VC: 6 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","lowerLimit":"-10","upperLimit":"200"},{"groupId":"OG002","value":"70.0","lowerLimit":"-10","upperLimit":"200"},{"groupId":"OG003","value":"30.0","lowerLimit":"-470","upperLimit":"410"},{"groupId":"OG004","value":"30.0","lowerLimit":"-470","upperLimit":"410"}]}]},{"title":"The change from baseline in VC: 12 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110.0","lowerLimit":"-90","upperLimit":"140"},{"groupId":"OG002","value":"110.0","lowerLimit":"-90","upperLimit":"140"},{"groupId":"OG003","value":"0.0","lowerLimit":"-370","upperLimit":"940"},{"groupId":"OG004","value":"0.0","lowerLimit":"-370","upperLimit":"940"}]}]},{"title":"The change from baseline in VC: 18 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-60.0","lowerLimit":"-70","upperLimit":"90"},{"groupId":"OG002","value":"-60.0","lowerLimit":"-70","upperLimit":"90"},{"groupId":"OG003","value":"-70.0","lowerLimit":"-700","upperLimit":"1250"},{"groupId":"OG004","value":"-70.0","lowerLimit":"-700","upperLimit":"1250"}]}]},{"title":"The change from baseline in VC: 24 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-290.0","lowerLimit":"-630","upperLimit":"50"},{"groupId":"OG002","value":"-290.0","lowerLimit":"-630","upperLimit":"50"},{"groupId":"OG003","value":"-50.0","lowerLimit":"-570","upperLimit":"1480"},{"groupId":"OG004","value":"-50.0","lowerLimit":"-570","upperLimit":"1480"}]}]},{"title":"The change from baseline in VC: 30 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-240.0","lowerLimit":"-510","upperLimit":"30"},{"groupId":"OG002","value":"-240.0","lowerLimit":"-510","upperLimit":"30"},{"groupId":"OG003","value":"20.0","lowerLimit":"-530","upperLimit":"1410"},{"groupId":"OG004","value":"20.0","lowerLimit":"-530","upperLimit":"1410"}]}]},{"title":"The change from baseline in VC: 39 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-305.0","lowerLimit":"-600","upperLimit":"-10"},{"groupId":"OG002","value":"-305.0","lowerLimit":"-600","upperLimit":"-10"},{"groupId":"OG003","value":"30.0","lowerLimit":"-660","upperLimit":"870"},{"groupId":"OG004","value":"30.0","lowerLimit":"-660","upperLimit":"870"}]}]},{"title":"The change from baseline in VC: 48 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"-480","upperLimit":"-480","comment":"because of 1 participant data only"},{"groupId":"OG002","value":"NA","lowerLimit":"-480","upperLimit":"-480","comment":"because of 1 participant data only"},{"groupId":"OG003","value":"15.0","lowerLimit":"-100","upperLimit":"910"},{"groupId":"OG004","value":"15.0","lowerLimit":"-100","upperLimit":"910"}]}]},{"title":"The change from baseline in VC: 57 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"-820","upperLimit":"-820","comment":"because of 1 participant data only"},{"groupId":"OG002","value":"NA","lowerLimit":"-820","upperLimit":"-820","comment":"because of 1 participant data only"},{"groupId":"OG003","value":"-20.0","lowerLimit":"-70","upperLimit":"1090"},{"groupId":"OG004","value":"-20.0","lowerLimit":"-70","upperLimit":"1090"}]}]},{"title":"The change from baseline in VC: 66 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"-990","upperLimit":"-990","comment":"because of 1 participant data only"},{"groupId":"OG002","value":"NA","lowerLimit":"-990","upperLimit":"-990","comment":"because of 1 participant data only"},{"groupId":"OG003","value":"300.0","lowerLimit":"-110","upperLimit":"710"},{"groupId":"OG004","value":"300.0","lowerLimit":"-110","upperLimit":"710"}]}]},{"title":"The change from baseline in VC: 75 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"175.0","lowerLimit":"-400","upperLimit":"750"},{"groupId":"OG004","value":"175.0","lowerLimit":"-400","upperLimit":"750"}]}]},{"title":"The change from baseline in VC: 84 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"145.0","lowerLimit":"-580","upperLimit":"870"},{"groupId":"OG004","value":"145.0","lowerLimit":"-580","upperLimit":"870"}]}]},{"title":"The change from baseline in VC: 93 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"-205.0","lowerLimit":"-890","upperLimit":"480"},{"groupId":"OG004","value":"-205.0","lowerLimit":"-890","upperLimit":"480"}]}]},{"title":"The change from baseline in VC: 102 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"NA","lowerLimit":"480","upperLimit":"480","comment":"because of 1 participant data only"},{"groupId":"OG004","value":"NA","lowerLimit":"480","upperLimit":"480","comment":"because of 1 participant data only"}]}]},{"title":"The change from baseline in VC: 111 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"NA","lowerLimit":"280","upperLimit":"280","comment":"because of 1 participant data only"},{"groupId":"OG004","value":"NA","lowerLimit":"280","upperLimit":"280","comment":"because of 1 participant data only"}]}]},{"title":"The change from baseline in FVC: 6 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-50","upperLimit":"120"},{"groupId":"OG002","value":"0.0","lowerLimit":"-50","upperLimit":"120"},{"groupId":"OG003","value":"35.0","lowerLimit":"-380","upperLimit":"390"},{"groupId":"OG004","value":"35.0","lowerLimit":"-380","upperLimit":"390"}]}]},{"title":"The change from baseline in FVC: 12 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","lowerLimit":"-110","upperLimit":"90"},{"groupId":"OG002","value":"80.0","lowerLimit":"-110","upperLimit":"90"},{"groupId":"OG003","value":"10.0","lowerLimit":"-400","upperLimit":"1030"},{"groupId":"OG004","value":"10.0","lowerLimit":"-400","upperLimit":"1030"}]}]},{"title":"The change from baseline in FVC: 18 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","lowerLimit":"-110","upperLimit":"0"},{"groupId":"OG002","value":"-20.0","lowerLimit":"-110","upperLimit":"0"},{"groupId":"OG003","value":"-140.0","lowerLimit":"-860","upperLimit":"1280"},{"groupId":"OG004","value":"-140.0","lowerLimit":"-860","upperLimit":"1280"}]}]},{"title":"The change from baseline in FVC: 24 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-155.0","lowerLimit":"-390","upperLimit":"80"},{"groupId":"OG002","value":"-155.0","lowerLimit":"-390","upperLimit":"80"},{"groupId":"OG003","value":"-50.0","lowerLimit":"-610","upperLimit":"1520"},{"groupId":"OG004","value":"-50.0","lowerLimit":"-610","upperLimit":"1520"}]}]},{"title":"The change from baseline in FVC: 30 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-265.0","lowerLimit":"-570","upperLimit":"40"},{"groupId":"OG002","value":"-265.0","lowerLimit":"-570","upperLimit":"40"},{"groupId":"OG003","value":"150.0","lowerLimit":"-430","upperLimit":"1450"},{"groupId":"OG004","value":"150.0","lowerLimit":"-430","upperLimit":"1450"}]}]},{"title":"The change from baseline in FVC: 39 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-345.0","lowerLimit":"-530","upperLimit":"-160"},{"groupId":"OG002","value":"-345.0","lowerLimit":"-530","upperLimit":"-160"},{"groupId":"OG003","value":"-35.0","lowerLimit":"-530","upperLimit":"770"},{"groupId":"OG004","value":"-35.0","lowerLimit":"-530","upperLimit":"770"}]}]},{"title":"The change from baseline in FVC: 48 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"-480","upperLimit":"-480","comment":"because of 1 participant data only"},{"groupId":"OG002","value":"NA","lowerLimit":"-480","upperLimit":"-480","comment":"because of 1 participant data only"},{"groupId":"OG003","value":"70.0","lowerLimit":"-160","upperLimit":"800"},{"groupId":"OG004","value":"70.0","lowerLimit":"-160","upperLimit":"800"}]}]},{"title":"The change from baseline in FVC: 57 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"-800","upperLimit":"-800","comment":"because of 1 participant data only"},{"groupId":"OG002","value":"NA","lowerLimit":"-800","upperLimit":"-800","comment":"because of 1 participant data only"},{"groupId":"OG003","value":"60.0","lowerLimit":"-70","upperLimit":"880"},{"groupId":"OG004","value":"60.0","lowerLimit":"-70","upperLimit":"880"}]}]},{"title":"The change from baseline in FVC: 66 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"-880","upperLimit":"-880","comment":"because of 1 participant data only"},{"groupId":"OG002","value":"NA","lowerLimit":"-880","upperLimit":"-880","comment":"because of 1 participant data only"},{"groupId":"OG003","value":"300.0","lowerLimit":"-140","upperLimit":"740"},{"groupId":"OG004","value":"300.0","lowerLimit":"-140","upperLimit":"740"}]}]},{"title":"The change from baseline in FVC: 75 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"50.0","lowerLimit":"-550","upperLimit":"650"},{"groupId":"OG004","value":"50.0","lowerLimit":"-550","upperLimit":"650"}]}]},{"title":"The change from baseline in FVC: 84 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"10.0","lowerLimit":"-580","upperLimit":"600"},{"groupId":"OG004","value":"10.0","lowerLimit":"-580","upperLimit":"600"}]}]},{"title":"The change from baseline in FVC: 93 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"-230.0","lowerLimit":"-900","upperLimit":"440"},{"groupId":"OG004","value":"-230.0","lowerLimit":"-900","upperLimit":"440"}]}]},{"title":"The change from baseline in FVC: 102 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"NA","lowerLimit":"540","upperLimit":"540","comment":"because of 1 participant data only"},{"groupId":"OG004","value":"NA","lowerLimit":"540","upperLimit":"540","comment":"because of 1 participant data only"}]}]},{"title":"The change from baseline in FVC: 111 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"NA","lowerLimit":"490","upperLimit":"490","comment":"because of 1 participant data only"},{"groupId":"OG004","value":"NA","lowerLimit":"490","upperLimit":"490","comment":"because of 1 participant data only"}]}]}]},{"type":"SECONDARY","title":"Respiratory Function Tests (Forced Expiratory Volume in the First Second [FEV1])","populationDescription":"modified ITT population. Efficacy was analyzed using the efficacy analysis population (i.e., modified ITT population; mITT), separately for Phase 1 part (n=4), Phase 2 part (n=24) and Phase 2 part including 1 participant with MPM in Phase 1 part (n=25). In respiratory function tests, data from 1 participant with MPM in Phase 1 part were not collected.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"L","timeFrame":"Every 6 weeks from the first dose of BBI608 until Week 30, and then every 9 weeks from Week 31 [Actually up to Week 111]","groups":[{"id":"OG000","title":"NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG001","title":"MPM: BBI608 + Pem +CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG002","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG003","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."},{"id":"OG004","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part Including 1 Participant With MPM in Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"}]}],"classes":[{"title":"The change from baseline in FEV1: 6 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.160","lowerLimit":"-0.01","upperLimit":"0.16"},{"groupId":"OG002","value":"0.160","lowerLimit":"-0.01","upperLimit":"0.16"},{"groupId":"OG003","value":"0.050","lowerLimit":"-0.40","upperLimit":"0.33"},{"groupId":"OG004","value":"0.050","lowerLimit":"-0.40","upperLimit":"0.33"}]}]},{"title":"The change from baseline in FEV1: 12 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.070","lowerLimit":"0.03","upperLimit":"0.18"},{"groupId":"OG002","value":"0.070","lowerLimit":"0.03","upperLimit":"0.18"},{"groupId":"OG003","value":"-0.130","lowerLimit":"-0.33","upperLimit":"0.52"},{"groupId":"OG004","value":"-0.130","lowerLimit":"-0.33","upperLimit":"0.52"}]}]},{"title":"The change from baseline in FEV1: 18 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","lowerLimit":"-0.13","upperLimit":"0.16"},{"groupId":"OG002","value":"0.000","lowerLimit":"-0.13","upperLimit":"0.16"},{"groupId":"OG003","value":"-0.110","lowerLimit":"-0.56","upperLimit":"0.63"},{"groupId":"OG004","value":"-0.110","lowerLimit":"-0.56","upperLimit":"0.63"}]}]},{"title":"The change from baseline in FEV1: 24 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.010","lowerLimit":"-0.16","upperLimit":"0.14"},{"groupId":"OG002","value":"-0.010","lowerLimit":"-0.16","upperLimit":"0.14"},{"groupId":"OG003","value":"-0.040","lowerLimit":"-0.45","upperLimit":"0.78"},{"groupId":"OG004","value":"-0.040","lowerLimit":"-0.45","upperLimit":"0.78"}]}]},{"title":"The change from baseline in FEV1: 30 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.055","lowerLimit":"-0.23","upperLimit":"0.12"},{"groupId":"OG002","value":"-0.055","lowerLimit":"-0.23","upperLimit":"0.12"},{"groupId":"OG003","value":"-0.030","lowerLimit":"-0.29","upperLimit":"0.71"},{"groupId":"OG004","value":"-0.030","lowerLimit":"-0.29","upperLimit":"0.71"}]}]},{"title":"The change from baseline in FEV1: 39 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.140","lowerLimit":"-0.28","upperLimit":"0.00"},{"groupId":"OG002","value":"-0.140","lowerLimit":"-0.28","upperLimit":"0.00"},{"groupId":"OG003","value":"-0.050","lowerLimit":"-0.37","upperLimit":"0.26"},{"groupId":"OG004","value":"-0.050","lowerLimit":"-0.37","upperLimit":"0.26"}]}]},{"title":"The change from baseline in FEV1: 48 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"-0.060","upperLimit":"-0.060","comment":"because of 1 participant data only"},{"groupId":"OG002","value":"NA","lowerLimit":"-0.060","upperLimit":"-0.060","comment":"because of 1 participant data only"},{"groupId":"OG003","value":"0.115","lowerLimit":"-0.12","upperLimit":"0.39"},{"groupId":"OG004","value":"0.115","lowerLimit":"-0.12","upperLimit":"0.39"}]}]},{"title":"The change from baseline in FEV1: 57 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"-0.460","upperLimit":"-0.460","comment":"because of 1 participant data only"},{"groupId":"OG002","value":"NA","lowerLimit":"-0.460","upperLimit":"-0.460","comment":"because of 1 participant data only"},{"groupId":"OG003","value":"0.010","lowerLimit":"-0.07","upperLimit":"0.31"},{"groupId":"OG004","value":"0.010","lowerLimit":"-0.07","upperLimit":"0.31"}]}]},{"title":"The change from baseline in FEV1: 66 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"-0.570","upperLimit":"-0.570","comment":"because of 1 participant data only"},{"groupId":"OG002","value":"NA","lowerLimit":"-0.570","upperLimit":"-0.570","comment":"because of 1 participant data only"},{"groupId":"OG003","value":"0.085","lowerLimit":"-0.16","upperLimit":"0.33"},{"groupId":"OG004","value":"0.085","lowerLimit":"-0.16","upperLimit":"0.33"}]}]},{"title":"The change from baseline in FEV1: 75 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"-0.045","lowerLimit":"-0.42","upperLimit":"0.33"},{"groupId":"OG004","value":"-0.045","lowerLimit":"-0.42","upperLimit":"0.33"}]}]},{"title":"The change from baseline in FEV1: 84 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"-0.130","lowerLimit":"-0.44","upperLimit":"0.18"},{"groupId":"OG004","value":"-0.130","lowerLimit":"-0.44","upperLimit":"0.18"}]}]},{"title":"The change from baseline in FEV1: 93 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"-0.215","lowerLimit":"-0.66","upperLimit":"0.23"},{"groupId":"OG004","value":"-0.215","lowerLimit":"-0.66","upperLimit":"0.23"}]}]},{"title":"The change from baseline in FEV1: 102 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"NA","lowerLimit":"0.150","upperLimit":"0.150","comment":"because of 1 participant data only"},{"groupId":"OG004","value":"NA","lowerLimit":"0.150","upperLimit":"0.150","comment":"because of 1 participant data only"}]}]},{"title":"The change from baseline in FEV1: 111 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"NA","lowerLimit":"0.080","upperLimit":"0.080","comment":"because of 1 participant data only"},{"groupId":"OG004","value":"NA","lowerLimit":"0.080","upperLimit":"0.080","comment":"because of 1 participant data only"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"During a period from initial dosing of investigational drug to final evaluation in the follow-up observation period. up to 31 months for deaths, up to 11 months for Serious and Other (Not Including Serious) Adverse Events","description":"Safety analysis population \\[separately for Phase 1 part (n=4), Phase 2 part (n=24) and Phase 2 part including 1 participant with MPM in Phase 1 part (n=25)\\]","eventGroups":[{"id":"EG000","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","deathsNumAffected":2,"deathsNumAtRisk":4,"seriousNumAffected":0,"seriousNumAtRisk":4,"otherNumAffected":4,"otherNumAtRisk":4},{"id":"EG001","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","deathsNumAffected":19,"deathsNumAtRisk":24,"seriousNumAffected":7,"seriousNumAtRisk":24,"otherNumAffected":24,"otherNumAtRisk":24},{"id":"EG002","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part Including 1 Participant With MPM in Phase 1 Part)","description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","deathsNumAffected":21,"deathsNumAtRisk":25,"seriousNumAffected":7,"seriousNumAtRisk":25,"otherNumAffected":25,"otherNumAtRisk":25}],"seriousEvents":[{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Neuroendocrine carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":4},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":24},{"groupId":"EG002","numEvents":16,"numAffected":15,"numAtRisk":25}]},{"term":"Hearing impaired","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":25}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":22,"numAffected":14,"numAtRisk":24},{"groupId":"EG002","numEvents":22,"numAffected":14,"numAtRisk":25}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":4},{"groupId":"EG001","numEvents":54,"numAffected":24,"numAtRisk":24},{"groupId":"EG002","numEvents":55,"numAffected":25,"numAtRisk":25}]},{"term":"Faecal incontinence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":24},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":25}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":4},{"groupId":"EG001","numEvents":49,"numAffected":21,"numAtRisk":24},{"groupId":"EG002","numEvents":51,"numAffected":22,"numAtRisk":25}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":24},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":25}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":17,"numAffected":12,"numAtRisk":24},{"groupId":"EG002","numEvents":17,"numAffected":12,"numAtRisk":25}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":4},{"groupId":"EG001","numEvents":10,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":10,"numAffected":4,"numAtRisk":25}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":24},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":25}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":24},{"groupId":"EG002","numEvents":11,"numAffected":6,"numAtRisk":25}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":24},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":25}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":24},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":25}]},{"term":"Creatinine renal clearance decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":25}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":2,"numAtRisk":4},{"groupId":"EG001","numEvents":18,"numAffected":12,"numAtRisk":24},{"groupId":"EG002","numEvents":19,"numAffected":13,"numAtRisk":25}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":25}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":24},{"groupId":"EG002","numEvents":10,"numAffected":6,"numAtRisk":25}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":2,"numAtRisk":4},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":24},{"groupId":"EG002","numEvents":12,"numAffected":8,"numAtRisk":25}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":3,"numAtRisk":4},{"groupId":"EG001","numEvents":45,"numAffected":21,"numAtRisk":24},{"groupId":"EG002","numEvents":46,"numAffected":22,"numAtRisk":25}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":25}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":25}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":25}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":24},{"groupId":"EG002","numEvents":13,"numAffected":9,"numAtRisk":25}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":9,"numAffected":4,"numAtRisk":25}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":24},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":25}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":10,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":10,"numAffected":4,"numAtRisk":25}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":25}]},{"term":"Chromaturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":25}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":24},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":25}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":4},{"groupId":"EG001","numEvents":22,"numAffected":12,"numAtRisk":24},{"groupId":"EG002","numEvents":23,"numAffected":13,"numAtRisk":25}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (17.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":25}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Clinical Research (Oncology)","organization":"Sumitomo Dainippon Pharmaceutical","email":"cc@ds-pharma.co.jp","phone":"e-mail only"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-01-05","uploadDate":"2020-10-27T21:54","filename":"Prot_000.pdf","size":2479368},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-01-18","uploadDate":"2020-10-27T21:55","filename":"SAP_001.pdf","size":1264534}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D000086002","term":"Mesothelioma, Malignant"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D008654","term":"Mesothelioma"},{"id":"D000236","term":"Adenoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D018301","term":"Neoplasms, Mesothelial"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D010997","term":"Pleural Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000621033","term":"napabucasin"},{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"}]}},"hasResults":true}